(Hypertension. 1995;25:495-500.)
© 1995 American Heart Association, Inc.
Articles |
Effect of Chronic Treatment of Adult Spontaneously Hypertensive Rats With an Endothelin Receptor Antagonist
From the MRC Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montréal (Quebec, Canada).
Abstract We previously showed that endothelin-1 expression was increased in vascular endothelium of deoxycorticosterone acetate–salt hypertensive rats, whereas in spontaneously hypertensive rats (SHR) it is similar to or less than that in normotensive rats. Treatment with the combined endothelin type A/endothelin type B receptor antagonist bosentan moderately reduced blood pressure rise and nearly completely blunted the development of vascular hypertrophy, particularly in small arteries, in the deoxycorticosterone acetate–salt hypertensive model, suggesting a paracrine role for vascular endothelin-1 in the induction of blood vessel hypertrophy in some forms of experimental hypertension. In the present study we examined the effect of chronic oral treatment for 4 weeks of 12-week-old SHR and Wistar-Kyoto rats (WKY) with 100 mg/kg per day bosentan. Blood pressure rose to hypertensive levels similarly in bosentan-treated and untreated SHR; systolic pressure of WKY was also unaffected. The wet weights of the heart, of aortic segments, and of the mesenteric arterial bed were similar in treated and untreated SHR. When coronary, renal arcuate, mesenteric, and femoral small arteries were evaluated on a wire myograph, the media width and media-to-lumen ratio were greater and the lumen diameter was smaller in vessels from SHR relative to those from WKY, except in small arteries from the renal cortex, in which the lumen was not significantly different in both strains. The media cross-sectional area of small arteries from the four vascular beds was similar in both strains. Identical morphometric parameters were found in the four vascular beds in bosentan-treated and untreated rats of each strain. We conclude that endothelins do not play a role in the maintenance of elevated blood pressure or in vascular hypertrophy or remodeling in adult SHR. This study also showed similar morphometric changes consistent with remodeling in small arteries of the coronary, mesenteric, and femoral vascular beds of SHR, whereas the changes in renal cortical small arteries were consistent with vascular hypertrophy.
Key Words: arteries • blood pressure • hypertension, essential • hypertrophy • receptors, endothelin
This article has been cited by other articles:
 |
|
 |
|
  E. Belaidi, M. Joyeux-Faure, C. Ribuot, S. H. Launois, P. Levy, and D. Godin-Ribuot Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1309 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Ko, F. Amiri, N. R. Pandey, D. Javeshghani, E. Leibovitz, R. M. Touyz, and E. L. Schiffrin Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1789 - H1795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Brassard, F. Amiri, and E. L. Schiffrin Combined Angiotensin II Type 1 and Type 2 Receptor Blockade on Vascular Remodeling and Matrix Metalloproteinases in Resistance Arteries Hypertension, September 1, 2005; 46(3): 598 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Lee, M.-S. Lin, T.-F. Chou, C.-H. Tsai, and N.-C. Chang Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H220 - H227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Di Filippo, F. Rossi, E. Ongini, P. Del Soldato, M. Perretti, and M. D'Amico The Distinct Alterations Produced in Cardiovascular Functions by Prednisolone and Nitro-prednisolone (NCX-1015) in the Rat Highlight a Causal Role for Endothelin-1 J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1133 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Dina, T. Feres, A. C.M. Paiva, and T. B. Paiva Role of Membrane Potential and Expression of Endothelial Factors in Restenosis After Angioplasty in SHR Hypertension, January 1, 2004; 43(1): 131 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Tovar and J. G Gums Tezosentan in the Treatment of Acute Heart Failure Ann. Pharmacother., December 1, 2003; 37(12): 1877 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Pu, M. F. Neves, A. Virdis, R. M. Touyz, and E. L. Schiffrin Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling Hypertension, July 1, 2003; 42(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Iwanaga, Y. Kihara, K. Inagaki, Y. Onozawa, T. Yoneda, K. Kataoka, and S. Sasayama Differential Effects of Angiotensin II Versus Endothelin-1 Inhibitions in Hypertrophic Left Ventricular Myocardium During Transition to Heart Failure Circulation, July 31, 2001; 104(5): 606 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Touyz and E. L. Schiffrin Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Reinhart, L. C. Preusser, T. J. Opgenorth, C. D. Wegner, and B. F. Cox Endothelin and ETA receptors in long-term arterial pressure homeostasis in conscious nonhuman primates Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2000; 279(5): R1701 - R1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Intengan and E. L. Schiffrin Vasopeptidase Inhibition Has Potent Effects on Blood Pressure and Resistance Arteries in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, June 1, 2000; 35(6): 1221 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Intengan, G. Thibault, J.-S. Li, and E. L. Schiffrin Resistance Artery Mechanics, Structure, and Extracellular Components in Spontaneously Hypertensive Rats : Effects of Angiotensin Receptor Antagonism and Converting Enzyme Inhibition Circulation, November 30, 1999; 100(22): 2267 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zicha and J. Kunes Ontogenetic Aspects of Hypertension Development: Analysis in the Rat Physiol Rev, October 1, 1999; 79(4): 1227 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwanaga, Y. Kihara, K. Hasegawa, K. Inagaki, T. Yoneda, S. Kaburagi, M. Araki, and S. Sasayama Cardiac Endothelin-1 Plays a Critical Role in the Functional Deterioration of Left Ventricles During the Transition From Compensatory Hypertrophy to Congestive Heart Failure in Salt-Sensitive Hypertensive Rats Circulation, November 10, 1998; 98(19): 2065 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Oie, R. Bjonerheim, H. K. Grogaard, H. Kongshaug, O. A. Smiseth, and H. Attramadal ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H868 - H877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Moreau Endothelin in hypertension: A role for receptor antagonists? Cardiovasc Res, September 1, 1998; 39(3): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Herizi, B. Jover, N. Bouriquet, and A. Mimran Prevention of the Cardiovascular and Renal Effects of Angiotensin II by Endothelin Blockade Hypertension, January 1, 1998; 31(1): 10 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Li, R. M. Touyz, and E. L. Schiffrin Effects of AT1 and AT2 Angiotensin Receptor Antagonists in Angiotensin II-Infused Rats Hypertension, January 1, 1998; 31(1): 487 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Barton, L. V. d'Uscio, S. Shaw, P. Meyer, P. Moreau, and T. F. Luscher ETA Receptor Blockade Prevents Increased Tissue Endothelin-1, Vascular Hypertrophy, and Endothelial Dysfunction in Salt-Sensitive Hypertension Hypertension, January 1, 1998; 31(1): 499 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Moreau, L. V. d'Uscio, S. Shaw, H. Takase, M. Barton, and T. F. Luscher Angiotensin II Increases Tissue Endothelin and Induces Vascular Hypertrophy : Reversal by ETA-Receptor Antagonist Circulation, September 2, 1997; 96(5): 1593 - 1597. [Abstract] [Full Text]
|
|
|
|
|
|
P. Moreau, H. Takase, C. F. Kung, S. Shaw, and T. F. Luscher Blood Pressure and Vascular Effects of Endothelin Blockade in Chronic Nitric Oxide–Deficient Hypertension Hypertension, March 1, 1997; 29(3): 763 - 769. [Abstract] [Full Text]
|
|
|
|
|
|
P. Sventek, A. Turgeon, and E. L. Schiffrin Vascular Endothelin-1 Gene Expression and Effect on Blood Pressure of Chronic ETA Endothelin Receptor Antagonism After Nitric Oxide Synthase Inhibition With L-NAME in Normal Rats Circulation, January 7, 1997; 95(1): 240 - 244. [Abstract] [Full Text]
|
|
|
|
|
|
L. V. d'Uscio, P. Moreau, S. Shaw, H. Takase, M. Barton, and T. F. Luscher Effects of Chronic ETA-Receptor Blockade in Angiotensin II-Induced Hypertension Hypertension, January 1, 1997; 29(1): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Balakrishnan, H. D. Wang, V. Gopalakrishnan, T. W. Wilson, and J. R. McNeill Effect of an Endothelin Antagonist on Hemodynamic Responses to Angiotensin II Hypertension, November 1, 1996; 28(5): 806 - 809. [Abstract] [Full Text]
|
|
|
|
|
|
K. Skov, J. Fenger-Gron, and M. J. Mulvany Effects of an Angiotensin-Converting Enzyme Inhibitor, a Calcium Antagonist, and an Endothelin Receptor Antagonist on Renal Afferent Arteriolar Structure Hypertension, September 1, 1996; 28(3): 464 - 471. [Abstract] [Full Text]
|
|
|
|
|
|
B. Bartholomeusz, K. J. Hardy, A. S. Nelson, and P. A. Phillips Bosentan Ameliorates Cyclosporin A–Induced Hypertension in Rats and Primates Hypertension, June 1, 1996; 27(6): 1341 - 1345. [Abstract] [Full Text]
|
|
|
|
|
|
J.-M. Chillon, D. D. Heistad, and G. L. Baumbach Effects of Endothelin Receptor Inhibition on Cerebral Arterioles in Hypertensive Rats Hypertension, March 1, 1996; 27(3): 794 - 798. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Takeda, I. Miyamori, P. Wu, T. Yoneda, K. Furukawa, and R. Takeda Effects of an Endothelin Receptor Antagonist in Rats With Cyclosporine-Induced Hypertension Hypertension, December 1, 1995; 26(6): 932 - 936. [Abstract] [Full Text]
|
|